Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

Cancer

Volumn 88, Issue 11, 2000, Pages 2584-2589

  Sugiyama, Toru ^a,f   Kamura, Toshiharu ^a   Kigawa, Junzo ^b   Terakawa, Naoki ^b   Kikuchi, Yoshihiro ^c   Kita, Tunekazu ^c   Suzuki, Mitsuaki ^d   Sato, Ikuo ^d   Taguchi, Kouji ^e  

^a KURUME UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Clear cell carcinoma; Ovary; Serous adenocarcinoma; Survival

Indexed keywords

PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 0034213974     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5     Document Type: Article

References (20)

1. Schiller W. Mesonephroma ovarii. Am J Cancer 1939:35:1-21.
2. Serov SF, Scully RE, Sobin LH. International histologic classification of tumors. No. 9. Histologic typing of ovarian tumors. Geneva: World Health Organization, 1973.
3. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol 1971;37:860-7.
4. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-9.
5. Crozier MA, Copeland LJ, Silva EG, Gershenson DW, Stringer CA. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989;35:199-203.
6. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
7. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49:250-4.
8. Sugawa T, Umesaki N, Yajima A, Satoh S, Terashima Y, Ochiai K, et al. A group study on prognosis of ovarian cancer. Acta Obstet Gynaecol Jpn 1992;44:827-32.
9. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
10. Goff BA, Sainz dela Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-7.
11. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-8.
12. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996;78:2157-63.
13. Gorai I, Nakazawa T, Miyagi E, Hirahara F, Nagashima Y, Minaguchi H. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol 1995; 57:33-46.
14. Norris HJ, Robinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer 1971;4:1074-81.
15. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. In: Proceedings of the Symposium on Ovarian Cancer. Monogr Natl Cancer Inst 1975; 42:101-4.
16. Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-80.
17. Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian cancer. J Ciln Oncol 1996;14:2968-75.
18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334: 1-6.
19. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
20. Shimizu Y, Umezawa S, Utsugi K, Hasumi K, Fujiwara K, Kohno I. Combination of CPT-11 with mitomycin-C (MMC) for platinum-refractory clear cell (CCA) and mucinous (MCA) adenocarcinoma of the ovary [abstract 1393]. Proc Am Soc Clin Oncol 1999;18:361a.